196 related articles for article (PubMed ID: 30004823)
1. Refractory Neutropenia Secondary to Dual Immune Checkpoint Inhibitors That Required Second-Line Immunosuppression.
Meti N; Petrogiannis-Haliotis T; Esfahani K
J Oncol Pract; 2018 Aug; 14(8):514-516. PubMed ID: 30004823
[No Abstract] [Full Text] [Related]
2. Autoimmune polyradiculitis due to combination immunotherapy with ipilimumab and nivolumab for the treatment of metastatic melanoma.
Lasocki A; Smith K
J Clin Neurosci; 2020 Apr; 74():240-241. PubMed ID: 31983645
[TBL] [Abstract][Full Text] [Related]
3. Checkpoint Inhibitor-Associated Hypophysitis.
Chang LS; Yialamas MA
J Gen Intern Med; 2018 Jan; 33(1):125-127. PubMed ID: 28770379
[No Abstract] [Full Text] [Related]
4. [Meningeal syndrome in a patient treated with a combination of immune checkpoint inhibitors for a metastatic melanoma].
Bello-Chavolla OY; Cortes-Arroyo JE; Vargas-Vazquez A; Quiroz-Compean F; Leal-Gutierrez G; Barragan-Dessavre M; Martinez-Samano JE
Rev Neurol; 2018 Oct; 67(7):279-280. PubMed ID: 30232801
[TBL] [Abstract][Full Text] [Related]
5. Acute generalized exanthematous pustulosis associated with ipilimumab and nivolumab.
Page B; Borradori L; Beltraminelli H; Yawalkar N; Hunger RE
J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):e256-e257. PubMed ID: 28430376
[No Abstract] [Full Text] [Related]
6. Neurologic Complications: Effects of Ipilimumab and Nivolumab Therapy in Patients With Metastatic Melanoma.
Latchman J; Guastella A; Tofthagen C
Clin J Oncol Nurs; 2019 Aug; 23(4):355-358. PubMed ID: 31322610
[TBL] [Abstract][Full Text] [Related]
7. Type 1 diabetes in a melanoma patient treated with ipilimumab after nivolumab.
Omodaka T; Kiniwa Y; Sato Y; Suwa M; Sato M; Yamaguchi T; Sato A; Miyake T; Okuyama R
J Dermatol; 2018 Oct; 45(10):e289-e290. PubMed ID: 29667767
[No Abstract] [Full Text] [Related]
8. Enteritis with immune checkpoint inhibitor use.
Sanders D; Webber D; Chatur N
CMAJ; 2019 Oct; 191(40):E1106. PubMed ID: 31591098
[No Abstract] [Full Text] [Related]
9. Development of Poliosis Following Checkpoint Inhibitor Treatment for Cutaneous Melanoma.
Ediriwickrema LS; Liu CY; Kikkawa DO; Korn BS
Ophthalmic Plast Reconstr Surg; 2019; 35(5):e121-e122. PubMed ID: 31373986
[TBL] [Abstract][Full Text] [Related]
10. Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab.
Hantel A; Gabster B; Cheng JX; Golomb H; Gajewski TF
J Immunother Cancer; 2018 Jul; 6(1):73. PubMed ID: 30012206
[TBL] [Abstract][Full Text] [Related]
11. Bicytopenia in Primary Lung Melanoma Treated with Nivolumab.
Takahashi A; Kubo A; Mizuno S; Kasai K; Asai N; Yonezawa T; Kosaka K; Nishimura M; Tanaka H; Yokoe N; Tsuzuki T; Takami A; Yamaguchi E
Intern Med; 2019 Mar; 58(6):827-831. PubMed ID: 30449777
[TBL] [Abstract][Full Text] [Related]
12. Fatal myocarditis and rhabdomyositis in a patient with stage IV melanoma treated with combined ipilimumab and nivolumab.
Saibil SD; Bonilla L; Majeed H; Sotov V; Hogg D; Chappell MA; Cybulsky M; Butler MO
Curr Oncol; 2019 Jun; 26(3):e418-e421. PubMed ID: 31285688
[TBL] [Abstract][Full Text] [Related]
13. Combination Ipilimumab and Nivolumab for Metastatic Melanoma Associated With Ciliochoroidal Effusion and Exudative Retinal Detachment.
Tsui E; Madu A; Belinsky I; Yannuzzi LA; Freund KB; Modi YS
JAMA Ophthalmol; 2017 Dec; 135(12):1455-1457. PubMed ID: 29145556
[No Abstract] [Full Text] [Related]
14. Secondary haemophagocytic lymphohistiocytosis due to checkpoint inhibitor therapy.
Chin CK; Hall S; Green C; Van Hazel G; Spagnolo D; Cheah CY
Eur J Cancer; 2019 Jul; 115():84-87. PubMed ID: 31129384
[No Abstract] [Full Text] [Related]
15. Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.
Tan I; Malinzak M; Salama AKS
J Immunother Cancer; 2018 Jul; 6(1):77. PubMed ID: 30064495
[TBL] [Abstract][Full Text] [Related]
16. HBV-related acute hepatitis due to immune checkpoint inhibitors in a patient with malignant melanoma.
Koksal AS; Toka B; Eminler AT; Hacibekiroglu I; Uslan MI; Parlak E
Ann Oncol; 2017 Dec; 28(12):3103-3104. PubMed ID: 28945827
[No Abstract] [Full Text] [Related]
17. Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma.
Gao CA; Weber UM; Peixoto AJ; Weiss SA
J Immunother Cancer; 2019 Oct; 7(1):262. PubMed ID: 31623673
[TBL] [Abstract][Full Text] [Related]
18. Bullous pemphigoid induced by ipilimumab in a patient with metastatic malignant melanoma after unsuccessful treatment with nivolumab.
Kuwatsuka Y; Iwanaga A; Kuwatsuka S; Okubo Y; Murayama N; Ishii N; Hashimoto T; Utani A
J Dermatol; 2018 Jan; 45(1):e21-e22. PubMed ID: 28944534
[No Abstract] [Full Text] [Related]
19. Extracorporeal Photopheresis for Colitis Induced by Checkpoint-Inhibitor Therapy.
Apostolova P; Unger S; von Bubnoff D; Meiss F; Becher B; Zeiser R
N Engl J Med; 2020 Jan; 382(3):294-296. PubMed ID: 31940706
[No Abstract] [Full Text] [Related]
20. Dual checkpoint inhibitor-associated eosinophilic enteritis.
Yang J; Lagana SM; Saenger YM; Carvajal RD
J Immunother Cancer; 2019 Nov; 7(1):310. PubMed ID: 31730503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]